Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + vandetanib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel + vandetanib is a combination therapy that pairs docetaxel, a taxane chemotherapeutic agent, with vandetanib, a tyrosine kinase inhibitor. Vandetanib inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. The combination alters the balance of proapoptotic and prosurvival proteins, potentially enhancing docetaxel-induced apoptosis in cancer cells. This combination has been studied in various cancer types including non-small cell lung cancer (NSCLC), prostate cancer, and urothelial cancer.
- Brand names
- Vandetanib + Taxotere
- Other names
- docetaxel + ZD6474
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on docetaxel + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + vandetanib.